1 **I**

2

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1

- 3
- 4 Yanmeng Feng^{1,§}, Yifan Zhang^{2,3,4,§}, Zhangyufan He^{2,4,§}, Haojie Huang⁵, Xiangxiang
- 5 Tian^{2,3,4}, Gang Wang⁴, Daihong Chen⁴, Yangin Ren², Ligiu Jia², Wanhai Wang³, Jing
- 6 Wu², Lingyun Shao², Wenhong Zhang^{2,6,7,8}, Heng Tang^{1,#}, Yanmin Wan^{2,7,9,#}
- 7
- ⁸ ¹ Hubei Provincial Center for Disease Control and Prevention, Wuhan 430065, China;
- ⁹ ² Department of Infectious Disease of Huashan Hospital, National Medical Center for
- 10 Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety
- 11 Emergency Response, Fudan University, Shanghai 200040, China;
- ³ Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key
- Laboratory of Laboratory Medicine of Henan Province, Zhengzhou 450052, China;
- ⁴ Department of laboratory medicine, Shanghai Public Health Clinical Center, Shanghai
 201508, China;
- ⁵Wuhan Pioneer Social Work Service Center, Wuhan 430071, China;
- ⁶ Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of
- Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032,
 China;
- ⁷ State Key Laboratory of Genetic Engineering, School of Life Science, Fudan
- 21 University, Shanghai 200438, China;
- ⁸ National Clinical Research Centre for Aging & Medicine, Huashan Hospital, Fudan
 University, Shanghai 200040, China;
- ⁹ Department of radiology, Shanghai Public Health Clinical Center, Shanghai 201508,
 China.
- ²⁶ [§] These authors contribute equally to this work.
- ²⁷ [#] Correspondence should be addressed to: Heng Tang, 867555881@qq.com; Yanmin
- 28 Wan, yanmin_wan@fudan.edu.cn
- 29
- 30 **Running title:** Evaluating the BIBP-CorV vaccine in PLWH
- 31 Word count: Abstract, 299; main text, 2393
- 32

33 Abstract

34 **Background** It has been proven that inactivated COVID-19 vaccines are safe and

35 effective in general population with intact immunity. However, their safety and

immunogenicity have not been demonstrated in people living with HIV (PLWH).

37 **Methods** 42 HIV-1 infected individuals who were stable on cART and 28 healthy

individuals were enrolled in this study. Two doses of an inactivated COVID-19 vaccine

39 (BIBP-CorV) were given 4 weeks apart. The safety and reactogenicity of the vaccine

40 were evaluated by observing clinical adverse events and solicited local and systemic

reactions. Humoral responses were measured by anti-spike IgG ELISA and surrogate

42 neutralization assays. Cell-mediated immune responses and vaccine induced T cell

43 activation were measured by flow cytometry.

44 **Findings** All the HIV-1 infected participants had a CD4⁺ T cell count of above 200

45 cells/µL both at baseline and 4 weeks after vaccination. No solicited adverse reaction

46 was observed among all participants. Similar binding antibody, neutralizing antibody

47 and S protein specific T cell responses were elicited in PLWH and healthy individuals.

Further analyses showed that PLWH with low baseline $CD4^+/CD8^+$ T cell ratios (<0.6)

49 generated lower antibody responses after vaccination than PLWH with medium (0.6~1.0)

or high (\geq 1.0) baseline CD4⁺/CD8⁺ T cell ratios (P<0.01). The CD3⁺, CD4⁺ and CD8⁺ T

cell counts of PLWH decreased significantly after vaccination, but it did not lead to any

⁵² adverse clinical manifestation. Moreover, we found that the general burden of HIV-1

⁵³ among the PLWH cohort decreased significantly (P=0.0192) after vaccination. And the

⁵⁴ alteration of HIV-1 viral load was not significantly associated with the vaccine induced

55 CD4⁺ T cell activation.

Interpretation Our data demonstrate that the inactivated COVID-19 vaccine is safe and
 immunogenic in PLWH who are stable on cART with unsuppressed CD4 counts.

58 **Funding** This work was funded by the National Natural Science Foundation of China

59 (Grant No. 81971559, 82041010).

60

61 **Key words**: HIV-1, COVID-19, Inactivated SARS-CoV-2 vaccine, Immunogenicity,

62 Safety

63

2

64 **Research in context**

65 Evidence before this study

- 66 The safety and efficacy of inactivated COVID-19 vaccines have been validated in
- 67 general population with intact immunity. However, their safety and immunogenicity have
- 68 not been demonstrated in people living with HIV (PLWH).
- 69

70 Added value of this study

- 71 Our study provides the first evidence to show humoral and cellular immune responses
- to an inactivated vaccine in PLWH who have been stable on cART with good CD4 cell
- counts. We found that participants with HIV-1 generated antibody and T cell responses
- comparable with those of healthy individuals after two-dose vaccination. The baseline
- 75 CD4/CD8 ratios while not the absolute CD4⁺ T cell counts were shown to be associated
- with the magnitudes of vaccine induced antibody responses. Moreover, we showed that
- the vaccine induced T cell activation did not increase the viral burden in PLWH on cART.
- On the contrary, the levels of plasma HIV-1 RNA decreased among a significant
- 79 percentage of PLWH.
- 80

81 Implications of all the available evidence

82 Our data demonstrate that the inactivated COVID-19 vaccine is safe and immunogenic

in PLWH who are stable on cART with unsuppressed CD4 counts and indicate that this

- vaccine might be protective and efficacious against COVID-19 for people with HIV.
- 85
- 86
- 00
- 87
- 88
- 89
- 90
- 91
- 92
- 0.2
- 93
- 94

95 Introduction

- 96 Even though the well-controlled HIV infection per se is not found as a risk factor of
- ⁹⁷ increased SARS-CoV-2 prevalence,^{1,2} it is alerted that the compromised immunities and
- 98 the high frequencies of comorbidities may render excessive challenges to this
- 99 population.^{3,4} A more recently released WHO report (WHO reference number:
- 100 WHO/2019-nCoV/Clinical/HIV/2021.1) suggests that HIV infection appears to be a
- significant independent risk factor for both severe/critical COVID-19 presentation at
- 102 hospital admission and in-hospital mortality. Vaccination against SARS-CoV-2 for
- 103 PLWH has also been recommended by WHO and health authorities of many countries.
- 104 However, as a clinical observation showed that SARS-CoV-2 natural infection induced
- 105 lower protective antibody responses in people with HIV,⁵ it is concerned that the
- 106 immunogenicity of COVID-19 in PLWH might be weak. The anxiety escalated when the
- news released from the Novavax COVID-19 vaccine study suggested that HIV infection
- ¹⁰⁸ might dampen the vaccine effectiveness.⁶
- 109 Reassuringly, more recently published data showed that both the messenger RNA
- vaccine and the ChAdOx1 nCoV-19 vaccine could elicit protective antibody responses
- in PLWH comparable with those in healthy individuals.⁷⁻¹⁰ In this study, we compared
- the antibody responses to two-dose inactivated SARS-CoV-2 vaccination between
- 113 healthy vaccinees and HIV-1 infected individuals stable on cART. We demonstrated that
- the inactivated COVID-19 vaccine was immunogenic and safe in PLWH. Baseline
- 115 CD4⁺/CD8⁺ T cell ratios were found to be associated with both the RBD binding
- antibody and the neutralizing antibody responses in PLWH.
- 117

118 Materials and methods

119 Study design and participants

- 120 In this open-label two-arm non-randomized study, we enrolled a cohort of HIV-1 infected
- individuals (n=42) who were stable on cART and under routine follow-up at
- 122 Hubei Provincial Center for Disease Control and Prevention, China and a cohort of
- healthy individuals (n=28). Written informed consent was obtained from all participants,
- and the study was approved by the Research Ethics Committee of Hubei CDC

- 125 (approval reference number: HBCDC-AF/SC-08/02.0). The demographical
- 126 characteristics of the enrolled vaccinees were depicted in Table 1.
- 127

128 Peripheral lymphocyte count and plasma HIV-1 viral RNA detection

- 129 The peripheral lymphocyte counts and plasma HIV-1 viral RNA detections for HIV-1
- 130 infected individuals were performed using the BD Multitest[™] CD3 FITC / CD8 PE /
- 131 CD45 PerCP / CD4 APC reagent and the COBAS® AmpliPrep / COBAS® TaqMan® HIV-
- 132 1 Test (v2.0) kit, respectively. All the detections were conducted following the
- 133 manufacturers` instructions in the clinical laboratory of Shanghai Public Health Clinical
- 134 Center.
- 135

136Titration of SARS-CoV-2 RBD binding antibody

- 137 In-house enzyme-linked immunosorbent assays (ELISA) were developed to measure
- 138 SARS-CoV-2 RBD specific binding antibodies. High-binding 96-well EIA plates (Cat#
- 139 9018, Corning, USA) were coated with purified SARS-CoV-2 RBD protein (Cat# 40591-
- 140 V08H, Sino Biological, China) at a final concentration of 1µg/ml in carbonate/bi-
- 141 carbonate coating buffer (30mM NaHCO₃,10mM Na₂CO₃, pH 9.6). Subsequently, the
- 142 plates were blocked with 1×PBS containing 5% skimmed milk for 1 hour at 37°C. Next,
- ¹⁴³ 50µl of diluted human plasma was added to each well. After 1-hour incubation at 37°C,
- the plates were washed with 1×PBS containing 0.05% Tween20 for 5 times. Then, 50µl
- of an HRP labeled goat anti-human IgG antibody (Cat# ab6759, Abcam, UK) diluted in
- 146 1×PBS containing 5% skimmed milk were added to each well and incubated for 1 hour
- at 37°C. After a second round of wash, 50µl of TMB substrate reagent (Cat# MG882,
- MESGEN, China) was added to each well. 15 minutes later, the color development was
- stopped by adding 50 μ I of 1M H₂SO₄ to each well and the values of optical density at
- 150 OD450_{nm} and OD630_{nm} were measured using 800 TS microplate reader (Cat# 800TS,
- 151 Biotek, USA).
- 152

153 **Quantification of SARS-CoV-2 neutralizing antibodies**

154 The neutralizing antibodies against SARS-CoV-2 were detected using a commercialized

surrogate neutralization test developed by Suzhou Xinbo Biotechnology Ltd. Company

156 (PerkinElmer, China). The rationale and method of this assay have been elaborated in previous studies.^{11,12} Briefly, plasma samples were firstly incubated with acridinium 157 158 ester labeled SARS-CoV-2 RBD for 15 min at room temperature. Then, magnetic beads coated with purified human ACE2 protein were added into the mixture and incubated for 159 160 15 min. After washing, the acridinium ester labeled RBD bound with the magnetic beads were measured by a chemiluminescent reaction. The concentrations of SARS-CoV-2 161 162 neutralizing antibody correlate negatively with the luminescence intensities, which can be quantified by establishing a standard curve. 163

164

165 Flowcytometry assays

To minimize measurement errors, freshly isolated PBMCs were preserved in liquid 166 nitrogen until the last follow-up was completed. Upon recovery, the PBMCs were 167 washed twice with R10 (RPMI1640 with 10% FBS). After counting, 1 million live (trypan 168 blue negative) cells from each sample were added to 96-well round bottom plates and 169 incubated with either R10 or R10 containing synthesized spike protein peptides 170 (0.6µg/ml for each peptide) overnight. Then, the cells were washed and stained 171 sequentially with live/dead dye(Zombie Aqua Fixable Viability Kit, cat#423101, 172 BioLegend), surface marker antibodies (Anti-human-CD3-APC/cyanine 7, cat#300318, 173 BioLegend: anti-human-CD4-BV605, cat#566148, BioLegend: anti-human-CD8-APC, 174 175 cat#344722, BioLegend; anti-human-HLA-DR-BV421, cat#307636, BioLegend; antihuman-CD38-Percp-Cy5.5, cat#551400, BD Pharmingen) and an intracellular IFN-y 176 177 antibody (anti-human-IFN-y-PE, cat#502509, BioLegend). Stained samples were analyzed using a BD Fortessa flow cytometer and data were analyzed with FlowJo 178 179 software version 10 (TreeStar Inc., Ashland, OR, USA). The gating strategy is shown in Supplementary figure 1. The evaluation of T cell activation was based on the data 180 generated from wells incubated with R10. 181

182

183 Statistical analysis

All the statistical analyses were conducted using Graphpad Prism 9 (GraphPad

- 185 Software, USA). Normality tests were performed before all downstream statistical
- analyses except the Chi square test. Comparisons between two groups were performed

- by the method of *t*-test. Differences among multiple groups were compared by the
- 188 method of one-way ANOVA. The contingency analysis was done using the method of

189 Chi-square test.

190

191 Role of the funding source

The funding source was not involved in study design, data collection and analysis, data
interpretation, the writing of the report, and the decision to submit the paper for
publication.

195

196 **Results**

197 Baseline characteristics of PLWH and HIV related events after vaccination

In this study, 28 healthy individuals and 42 PLWH were inoculated with two doses of the

- inactivated vaccine (BIBP-CorV) produced by Beijing Institute of Biological Products on
- 200 22 April 2021 and 25 May 2021, respectively. PLWH were slightly older than the control
- 201 (42.74 \pm 10.17 versus 37.79 \pm 8.804 years, p=0.0392). The gender composition and the
- mean BMI were similar between PLWH and healthy individuals (Table 1). All the HIV-1
- infected individuals have been on cART since being diagnosed with HIV-1 and have a
- peripheral CD4⁺ T cell count of >200 cells/ μ L. No solicited adverse reaction was
- 205 observed among all participants. None of PLWH developed HIV-related clinical events
- during the study period from 22 April 2021 to 25 June 2021.
- At the beginning of vaccination, 22 patients had an undetectable plasma viral load, 8
- 208 patients had detectable viral loads below 20 copies/ml and 12 patients had detectable
- viral loads beyond 20 copies/ml (Table 2). Unexpectedly, we found that the general viral
- burden among PLWH decreased after vaccination: 34 patients had an undetectable
- 211 plasma viral load, 4 patients had detectable viral loads below 20 copies/ml and 4
- 212 patients had detectable viral loads beyond 20 copies/ml (P=0.0192) (Table 2).
- 213 Meanwhile, our data also showed that the peripheral T cell counts decreased
- significantly after vaccination, but the CD4⁺/CD8⁺ T cell ratios remained stable (Table 2).
- 215
- The inactivated SARS-CoV-2 vaccine elicited comparable antibody and T cell
- 217 responses in PLWH with those in healthy individuals

To evaluate the immunogenicity of the inactivated SARS-CoV-2 vaccine in our cohorts,

- 219 peripheral blood samples were collected at baseline, 4 weeks after the first dose and 4
- weeks after the second dose, respectively. The results of RBD binding antibody assays
- showed that the inactivated vaccine induced similar levels of RBD binding antibodies in
- the two cohorts after both the first and the second dose (Fig.1A). We found that the
- average fold increase of RBD binding antibody was significantly lower in PLWH (Fig.1B),
- which was presumably due to the relatively high background antibody levels in this
- cohort (Fig.1A). Neutralizing antibody responses were elicited in most participants after
- two doses of vaccination (Fig. 1D and 1E) and the magnitudes were similar between
- PLWH and the healthy control (Fig. 1F). In addition, we also found that the mean levels
- of S2 binding antibodies were similar between PLWH and healthy individuals both at
- baseline and 4 weeks post second vaccination (Supplementary Figure 2).
- 230 The results of flowcytometry assays showed that two-dose inactivated SARS-CoV-2
- vaccine induced significant T cell responses in both HC and PLWH (Fig.2). Similar
- magnitudes of S protein specific CD4⁺ (Fig. 2A) and CD8⁺ (Fig. 2B) T cell responses
- were observed in the two cohorts.
- 234

Baseline CD4/CD8 ratios were associated with antibody responses after the vaccination in the cohort of PLWH

237 To understand whether the baseline immune status can influence the vaccine induced antibody responses in PLWH, we further analyzed the relationships between baseline T 238 239 cell counts and post vaccination antibody responses. Our data showed that neither the CD4⁺ T cell counts nor the CD8⁺ T cell counts at baseline correlated with the vaccine 240 241 induced antibody responses (Data not shown). While, the CD4⁺/CD8⁺ T cell ratios at baseline were found to be associated with antibody responses after the second dose of 242 243 vaccination (Fig.3). More specifically, the average RBD binding and neutralizing antibody responses of HIV-1 positive vaccinees with low baseline CD4⁺/CD8⁺ T cell 244 245 ratios (<0.6) were significantly lower than those with medium (0.6-1.0) or high (\geq 1.0) baseline CD4⁺/CD8⁺ T cell ratios (Fig.3A and 3B). Slightly different from the RBD 246 247 binding antibody and the nAb responses, we observed that S2 binding antibody responses in HIV-1 positive vaccinees with medium baseline CD4⁺/CD8⁺ T cell ratios 248

- were significantly higher than those with both low and high baseline CD4⁺/CD8⁺ T cell
- ratios (Fig.3C). We also analyzed the impacts of baseline CD4⁺/CD8⁺ T cell ratios on T
- cell responses and found that there was no significant difference among PLWH with low,
- ²⁵² medium and high baseline CD4⁺/CD8⁺ T cell ratios (Supplementary figure 3).
- 253

The patterns of vaccine induced T cell activation were different between HC and PLWH

- Vaccine induced activation of T cells was considered as a major constraint that might 256 compromise vaccine conferred benefits in PLWH.¹³⁻¹⁵ To investigate whether the 257 vaccine induced T cell activation was associated with the observed fluctuation of HIV-1 258 259 viral load, we measured the expressions of CD38 and HLA-DR on CD4⁺ and CD8⁺ T cells by flowcytometry. We observed that the patterns of vaccine induced T cell 260 activation were different between HC and PLWH (Fig.4). Of note, our data showed that 261 the percentages of CD38⁺HLA-DR⁻ CD4⁺ T cells (Fig.4B) increased, while the 262 percentages of CD38⁻HLA-DR⁺ CD8⁺ T cells (Fig.4D) decreased in PLWH after 263 vaccination. The decrease of CD38⁻HLA-DR⁺CD8⁺ T cells has been reported by a 264 previous study,¹³ however, the underlying mechanism is not clear. We further analyzed 265 the association between the observed T cell activation and plasma viral load fluctuation. 266 Although no statistical significance was reached, our results showed that the vaccine 267 induced fold-changes of CD38⁺HLA-DR⁻, CD38⁻HLA-DR⁺ and CD38⁺HLA-DR⁺CD4⁺ T 268 cells tended to be higher in viral increased PLWH (Supplementary figure 4). 269
- 270

271 **Discussion**

272 Even if the replication of HIV is controlled by cART, it can still be harder for PLWH to defend against infectious diseases.¹⁶ Therefore, vaccination is recommended for PLWH 273 whose peripheral CD4⁺ T cell counts are more than 200 cells/µL.¹⁷ However, due to the 274 compromised immune status, the vaccine elicited immune responses might be impaired 275 in PLWH.¹⁸⁻²¹ The efficacies of COVID-19 vaccines in PLWH were also seriously 276 concerned, because it has been suggested that HIV-1 infection could alter the host 277 immune responses against SARS-CoV-2.²² Here, we provided evidence showing that 278 an inactivated SARS-CoV-2 vaccine (BIBP-CorV) was immunogenic and safe in PLWH. 279

Importantly, our data demonstrated that the inactivated vaccine induced comparableantibody and T cell responses between PLWH and HC.

282 All the HIV-1 positive participants in our cohort had a CD4⁺ T cell count of >200 cells/µL both at baseline and 4 weeks post vaccination. We found a statistically significant 283 284 decrease in CD4⁺ T cell count between the baseline levels and those measured following the second vaccination. The decrease of CD4⁺ T cell count after vaccination 285 286 had also been observed in PLWH inoculated with the BNT162b2 mRNA vaccine and several other vaccines usually recommended for PLWH.^{23,24} Increases in activated T 287 cells were found to be associated with decreases in CD4⁺ T cell count among PLWH 288 received vaccination,²⁴ but the reason is still not clear. Of note, both our and other 289 290 studies did not identify any adverse clinical manifestation that was associated with the drop of CD4⁺ T cell count.^{23,24} Stable cART might be crucial to counteract the potential 291 vaccine related deleterious effect in PLWH according to a recently published case 292 report, which observed viral activation and CD4⁺ T cell loss in a treatment-naïve HIV-293 positive patient after receiving two doses of inactivated COVID-19 vaccines.²⁵ 294 Quite surprisingly, we observed a significant drop of general viral burden in the PLWH 295 cohort after vaccination. As percentages of activated T cells may correlate with HIV-1 296 replication, we further evaluated the vaccine induced T cell activation by measuring the 297 expressions of CD38 and HLA-DR on T cells. We found that the percentages of 298 299 CD38⁺HLA-DR⁻CD4⁺ T cells and CD38⁺HLA-DR⁺CD4⁺ T cells increased significantly after vaccination. We speculate that the elimination of activated HIV-1 infected CD4⁺ T 300 cells by cART or autologous CTLs might account for the observed drop of HIV burden in 301 the PLWH cohort. 302

303 Despite the generally comparable antibody responses between PLWH and healthy individuals, we demonstrated that HIV-1 infected vaccinees with low baseline 304 305 CD4⁺/CD8⁺ T cell ratio (<0.6) generated weaker antibody responses after vaccination, which was in line with previous reports showing that CD4⁺/CD8⁺ T cell ratios could 306 predict vaccine induced antibody responses in HIV-1 infected patients and HIV 307 negative elderly.^{26,27} Additionally, we showed that the baseline CD4⁺/CD8⁺ T cell ratios 308 did not impact the induction of specific T cell responses. Given that most vaccine 309 induced antibody responses are CD4⁺ T cell dependent, a potential explanation for the 310

- above phenomena is that the low CD4⁺/CD8⁺ T cell ratio might reflect the suboptimal
- 312 support for antibody responses.
- A major limitation of this study is the inadequate follow-up, which do not allow us to
- compare the persistence of antibody responses between PLWH and the healthy control.
- 315 Despite of this limitation, our study demonstrates that the inactivated COVID-19 vaccine
- was immunogenic and safe in PLWH stable on cART.
- 317

318 **Declaration of interests**

- 319 The authors declare no conflict of interest.
- 320

321 Author contributions

- 322 YW and HT were involved in the study design and supervision; YF, YZ, ZH, XT
- 323 GW, DC and LJ were involved in data collection; YR, WW, JW, LS, WZ and YW
- performed the data analysis; YW, YF and HT drafted the manuscript; WZ, LS, YW and
- 325 HT revised the manuscript. HH coordinated the enrollment of PLWH. The underlying
- data have been verified by YF and YW.
- 327

328 Data sharing

- Anonymized participant-level data will be made available 3 months following publication,
- upon requests directed to the corresponding author. After being approved by the
- sponsors (Fudan University and Hubei provincial CDC) and investigators
- 332 , the data can be shared through a secure online platform. All data will be made
- available for a minimum of 5 years after publication.
- 334

335 Acknowledgments

- We thank Dr. Lianguo Ruan from Wuhan Jinyintan Hospital for his help in PLWH cohort
- enrollment. We thank the volunteers who participated in this study. This work was
- funded by the National Natural Science Foundation of China (Grant No. 81971559,
- **82041010**).
- 340

341 References

- 1. Kanwugu ON, Adadi P. HIV/SARS-CoV-2 coinfection: A global perspective. *Journal of medical virology*
- 343 2021; **93**(2): 726-32.
- 2. Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in adults living with
- 345 HIV. *The lancet HIV* 2021; 8(5): e294-e305.
 346 3. Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 Among People Living with HIV: A
- 347 Systematic Review. AIDS and Behavior 2021; **25**(1): 85-92.
- 4. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in
- HIV/AIDS patients: a systematic review. *HIV medicine* 2020; **21**(9): 567-77.
- 350 5.Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus
- neutralising antibody titres after infection, compared by HIV status: a matched case-control
- observational study. *The lancet HIV* 2021; **8**(6): e334-e41.
- 6.Callaway E, Mallapaty S. Novavax offers first evidence that COVID vaccines protect people against
 variants. *Nature* 2021; **590**(7844): 17.
- 355 7. Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA Vaccine Elicits Robust Humoral
- and Cellular Immune Responses in People Living with HIV. *Clinical infectious diseases : an official*
- 357 *publication of the Infectious Diseases Society of America* 2021.
- 8.Ruddy JA, Boyarsky BJ, Bailey JR, et al. Safety and antibody response to two-dose SARS-CoV-2
- 359 messenger RNA vaccination in persons with HIV. *AIDS (London, England)* 2021.
- 360 9.Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222)
- vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *The lancet HIV* 2021; 8(8): e474-e85.
- 363 10.Spinelli MA. SARS-CoV-2 vaccination in people with HIV. *The lancet HIV* 2021; **8**(8): e455-e6.
- 11.Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun* 2021; **12**(1): 63.
- 12.Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist
 for months. *Science (New York, NY)* 2020; **370**(6521): 1227-30.
- 368 13.Onlamoon N, Unpol P, Boonchan M, et al. Immune activation and viral replication after vaccination
- with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy. *Disease markers* 2013; **35**(4): 221-7.
- 14.Hu H, Eller MA, Zafar S, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5
 naturally exposed and recombinant Ad5-HIV vaccinated individuals. 2014; **111**(37): 13439-44.
- 15.Immunization with Both T Cell-Dependent and T Cell-Independent Vaccines Augments HIV Viral Load
 Secondarily to Stimulation of Tumor Necrosis Factor α. 1998; 14(9): 727-34.
- 375 16.Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. *AIDS patient care and STDs* 2014;
 376 28(8): 397-410.
- 377 17.Frésard A, Gagneux-Brunon A, Lucht F, Botelho-Nevers E, Launay O. Immunization of HIV-infected
- adult patients French recommendations. *Human vaccines & immunotherapeutics* 2016; **12**(11): 272941.
- 380 18.Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients:
- systematic review and meta-analysis from a public health policy perspective. *PloS one* 2011; 6(12):
 e29249.
- 19.Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled
 HIV-infected individuals. *AIDS (London, England)* 2010; **24**(14): 2187-92.
- 385 20.George VK, Pallikkuth S, Parmigiani A, et al. HIV infection Worsens Age-Associated Defects in
- Antibody Responses to Influenza Vaccine. *The Journal of infectious diseases* 2015; **211**(12): 1959-68.
- 387 21. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 Infection in Infants Severely Impairs the Immune
- Response Induced by Bacille Calmette-Guérin Vaccine. *The Journal of infectious diseases* 2009; **199**(7):
- 389 982-90.

22.Karim F, Gazy I, Cele S, et al. HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease. 2020: 2020.11.23.20236828. 23.Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021. 24.Castro P, Plana M, González R, et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS research and human retroviruses 2009; **25**(12): 1249-59. 25.Gong C, Song X, Li X, Lu L, Li T. Immunological Changes after COVID-19 Vaccination in an HIV-Positive Patient. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2021. 26.Avelino-Silva VI, Miyaji KT, Hunt PW, et al. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. *PLoS neglected tropical diseases* 2016; **10**(12): e0005219. 27.Strindhall J, Ernerudh J, Mörner A, et al. Humoral response to influenza vaccination in relation to pre-vaccination antibody titres, vaccination history, cytomegalovirus serostatus and CD4/CD8 ratio. Infectious diseases (London, England) 2016; 48(6): 436-42. **Figure legends** Figure 1 The inactivated SARS-CoV-2 vaccine elicited comparable RBD binding antibody and neutralizing antibody responses in PLWH with those in the control

- 432 All participants in our study received two doses of the inactivated SARS-CoV-2 vaccine
- 433 (BIBP-CorV) produced by Beijing Institute of Biological Products at an interval of 4
- 434 weeks. Peripheral blood samples were collected at baseline, 4 weeks post the 1st dose
- and 4 weeks post the 2nd dose. RBD binding antibody (**A**, **B**, **C**) and neutralizing
- antibody (**D**, **E**, **F**) responses were measured and compared between PLWH (n=28) and
- healthy individuals (n=42). Statistical analyses were performed by the method of non-
- 438 parametric t test. ****, P<0.0001.
- 439

Figure 2 Comparisons of S protein specific T cell responses between PLWH and healthy individuals

- 442 S protein specific IFN-γ secreting T cells were measured using flowcytometry. The
- inactivated vaccine elicited similar levels of S protein specific CD4⁺ (A) and CD8⁺ T cell
- responses (**B**) in PLWH and HC. Statistical analyses were performed by the method of
- 445 non-parametric t test. ****, P<0.0001.
- 446

Figure 3 Baseline CD4⁺/CD8⁺ T cell ratios were associated with specific antibody responses after vaccination in PLWH

- 449 HIV-1 infected participants were stratified into 3 subgroups according to their baseline
- 450 $CD4^+/CD8^+$ T cell ratios (<0.6, 0.6~1.0 and ≥1.0). RBD binding antibody (**A**),
- 451 neutralizing antibody (**B**) and S2 binding antibody (**C**) responses were compared among
- the three subgroups. Statistical analysis for (A) was performed by the method of non-
- 453 parametric t test and statistical analyses for (**B**) and (**C**) were done by the method of
- 454 parametric t test. *, P<0.05; **, P<0.01; ***, P<0.001.
- 455

456 **Figure 4 The patterns of vaccine induced T cell activation were different between**

457 PLWH and HC

- The activation of T cells was assessed through detecting the expressions of CD38 and
- 459 HLA-DR on T cells. (A, B, C) The percentages of CD38⁻HLA-DR⁺, CD38⁺HLA-DR⁻ and
- 460 CD38⁺HLA-DR⁺ among CD4⁺ T cells. (**D**, **E**, **F**) The percentages of CD38⁻HLA-DR⁺,
- 461 CD38⁺HLA-DR⁻ and CD38⁺HLA-DR⁺ among CD8⁺ T cells. Statistical analyses were
- 462 performed by the method of two-way ANOVA. **, P<0.001; ****, P<0.0001.

	PLWH	НС	P value
Gender			
Man (n)	29	16	0 2220
Woman (n)	13	12	0.3228
Age (Year, mean±SD)	42.74±10.17	37·79±8·804	0.0392
BMI (Mean±SD)	23.97±6.967	24.07±3.8	0.2867

 Table 1
 Demographical characteristics of enrolled vaccinees

Note: PLWH, people living with HIV; HC, healthy control

	Baseline	4 weeks post the 2 nd dose	P value
T cell count (Mean ± SD cells/µL, n)			
CD3⁺ T	1550 ± 502, 28	1121 ± 336, 28	Paired t-test, <0.0001
CD4 ⁺ T	659 ± 222, 28	477 ± 151, 28	Paired <i>t</i> -test, <0.0001
CD8⁺ T	813 ± 361, 28	586 ± 240, 28	Paired t-test, <0.0001
CD4⁺ T/CD8⁺ T ratio Median, 25%-75% percentile, n)	0.86, 0.60-1.05, 28	0.82, 0.62-1.25, 28	Paired rank test, 0.519
Plasma viral load			
>20 copies/mL (n)	12	4	
<20 copies/mL (n)	8	4	Chi square test, 0.0192
Undetectable (n)	22	34	

Table 2 Peripheral T cell counts and plasma viral loads of PLWH

Figure 1 Comparisons of RBD binding antibody and neutralizing antibody responses between PLWH and healthy individuals

Α



Figure 2 Comparisons of S specific T cell responses between PLWH and healthy individuals



Figure 3 Baseline CD4/CD8 ratios were associated with the antibody responses after two doses of vaccination in PLWH



Figure 4 The patterns of vaccine induced T cell activation were different between PLWH and HC

